These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 16837676

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
    Ensrud K, LaCroix A, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R, Welty F, Cummings S.
    Circulation; 2010 Oct 26; 122(17):1716-24. PubMed ID: 20937977
    [Abstract] [Full Text] [Related]

  • 3. Lessons from RUTH.
    Pines A.
    Climacteric; 2006 Oct 26; 9(5):323-4. PubMed ID: 17000580
    [Abstract] [Full Text] [Related]

  • 4. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.
    Curr Med Res Opin; 2005 Sep 26; 21(9):1441-52. PubMed ID: 16197663
    [Abstract] [Full Text] [Related]

  • 5. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
    Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.
    J Bone Miner Res; 2004 Aug 26; 19(8):1270-5. PubMed ID: 15231013
    [Abstract] [Full Text] [Related]

  • 6. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators.
    J Natl Cancer Inst; 2004 Dec 01; 96(23):1751-61. PubMed ID: 15572757
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL.
    J Fam Pract; 2004 Oct 01; 53(10):789-96. PubMed ID: 15469774
    [Abstract] [Full Text] [Related]

  • 9. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA, Land SR.
    Menopause; 2008 Oct 01; 15(4 Suppl):797-803. PubMed ID: 18596601
    [Abstract] [Full Text] [Related]

  • 10. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D.
    Am J Med; 2009 Aug 01; 122(8):754-61. PubMed ID: 19540454
    [Abstract] [Full Text] [Related]

  • 11. Benefits and risks of raloxifene by vertebral fracture status.
    Sontag A, Wan X, Krege JH.
    Curr Med Res Opin; 2010 Jan 01; 26(1):71-6. PubMed ID: 19908937
    [Abstract] [Full Text] [Related]

  • 12. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett SA, Agnusdei D, Stuenkel CA.
    Menopause; 2009 Jan 01; 16(2):413-21. PubMed ID: 19092711
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar 01; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 15. Risk-benefit profiles of raloxifene for women.
    Stefanick ML.
    N Engl J Med; 2006 Jul 13; 355(2):190-2. PubMed ID: 16837684
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Raloxifene (Celvista, Evista)].
    Body JJ, Sternon J.
    Rev Med Brux; 2000 Feb 13; 21(1):35-41. PubMed ID: 10748686
    [Abstract] [Full Text] [Related]

  • 18. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M.
    Clin Calcium; 2004 Oct 13; 14(10):105-10. PubMed ID: 15577140
    [Abstract] [Full Text] [Related]

  • 19. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
    Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E.
    Am J Cardiol; 2006 Feb 15; 97(4):520-7. PubMed ID: 16461049
    [Abstract] [Full Text] [Related]

  • 20. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T.
    Clin Calcium; 2006 Sep 15; 16(9):1520-25. PubMed ID: 16951478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.